Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2006, Vol. 17 ›› Issue (3): 143 doi: 10.1016/S1001-8042(06)60028-6

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

PET radiopharmaceuticals for neuroreceptor imaging

S. M. AMETAMEY* P. A. SCHUBIGER   

  1. Center for Radiopharmaceutical Science of ETH, PSI and USZ, Department of Chemistry and Applied Biosciences of ETH, Zurich, Switzerland
PDF ShareIt Export Citation
S. M. AMETAMEY P. A. SCHUBIGER. PET radiopharmaceuticals for neuroreceptor imaging.Nuclear Science and Techniques, 2006, 17(3): 143     doi: 10.1016/S1001-8042(06)60028-6
Citations
Altmetrics

Abstract: Routine clinical PET radiopharmaceuticals for the noninvasive imaging of brain receptors, transporters, and enzymes are commonly labeled with positron emitting nuclides such as carbon-11 or fluorine-18. Certain minimal conditions need to be fulfilled for these PET ligands to be used as imaging agents in vivo. Some of these prerequisites are discussed and examples of the most useful clinical PET radiopharmaceuticals that have found application in the central nervous system are reviewed.

Key words: PET radiopharmaceuticals, Brain receptors, Carbon-11, Fluorine-18